Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
- 1 March 2020
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 180 (5), 895-914.e27
- https://doi.org/10.1016/j.cell.2020.02.019
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (456155)
- National Breast Cancer Foundation (IN-15-003)
- PA Research Foundation
- Cancer Council Queensland (1041390)
- University of Queensland
- Merck KGaA
This publication has 93 references indexed in Scilit:
- Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancersJournal of Translational Medicine, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Role of the Clathrin Terminal Domain in Regulating Coated Pit Dynamics Revealed by Small Molecule InhibitionCell, 2011
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- Dynamin- and Clathrin-Dependent Endocytosis in African Swine Fever Virus EntryJournal of Virology, 2010
- Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src@BMC Cell Biology, 2009
- TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2Cancer Research, 2009
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene, 2008
- The GTPase-Activating Protein GRAF1 Regulates the CLIC/GEEC Endocytic PathwayCurrent Biology, 2008
- PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate ApoptosisPLOS ONE, 2007